E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Immunogenicity of the mRNA BNT162b2 COVID-19 vaccine. |
Immunogeniciteit van het mRNA BNT162b2 COVID-19 vaccin. |
|
E.1.1.1 | Medical condition in easily understood language |
Immune response to the COVID-19 vaccine. |
Immuunreactie op het COVID-19 vaccin. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to analyze whether BCG-vaccination prior to COVID-19 vaccination can enhance the immunogenicity of the COVID‑19 mRNA vaccine developed by BioNTech and Pfizer. |
Het doel is te onderzoeken of BCG vaccinatiie de immunogeniciteit kan verhogen van het COVID-19 mRNA vaccin ontwikkeld door BioNTech/Pfizer. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to determine if antibody concentrations against SARS-CoV-2 antigens in nasal mucosal lining fluid at the various sampling time points can be detected and if prior BCG vaccination leads to more severe local or systemic reactions after COVID-19 vaccination.
|
Secundaire doelen zijn om te bepalen of antilichaam concentraties tegen SARS-CoV-2 antigenen in slijmvlies van de neus op verschillende tijdspunten gedetecteerd kunnen worden en of er in de BCG-groep na COVID-19 heftigere locale of systemische bijwerkingen optreden.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age equal to or above 18 years; - Written informed consent provided by the participant; - Receiving BioNTech/Pfizer COVID-19 vaccine per routine care; - Having received BCG-vaccination in the past 12 months OR never having received BCG-vaccination.
|
- Leeftijd ouder dan of gelijk aan 18 jaar. - Schriftelijke toestemming voor deelname; - Wordt via de reguliere zorg met het BioNTech/Pfizer COVID-19 vaccin gevaccineerd; - In de afgelopen 12 maanden gevaccineerd met BCG OF nooit een BCG vaccinatie gehad. |
|
E.4 | Principal exclusion criteria |
- Legally incapacitated or unwilling to provide informed consent; - History of COVID-19 infection, confirmed by a microbiological test. |
- Juridisch handelingsonbekwaam of geen schriftelijke toestemming willen geven; - Doorgemaakte COVID-19 infectie, bewezen met een microbiologische test. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Seroconversion of IgG to the SARS-CoV-2 spike protein at day 21 after the first dose of Pfizer/BioNTech BNT162B2. Seroconversion of antibodies is defined as a change from seronegative at baseline (pre-1st dose of Pfizer/BioNTech BNT162B2) to seropositive or a ≥four-fold titer increase if the participant is seropositive at baseline |
Seroconversie van IgG naar SARS-CoV-2 spike eiwit op dag 21 na de eerste injectie van het Pfizer/BioNTech BNT162B2 vaccin. Seroconversie van de antilichamen is gedefineerd als verandering van seronegatief bij aanvang/baseline (vóór de eerste injectie van het Pfizer/BioNTech BNT162B2 vaccin) naar seropositief of een viervoud verhoogde stijging van titer als de deelnemer bij aanvang/baseline seropositief was. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be analyzed when all blood samples of timepoint Day 21 have been collected. |
De primaire uitkomstmaat zal geanalyseerd worden zodra alle bloed samples van tijdspunt Dag 21 zijn verzameld. |
|
E.5.2 | Secondary end point(s) |
- Geometric mean concentrations (GMCs) of RBD- and S-specific IgG, IgA and IgM in serum at day 21, 35, month 6 and 12; - IgG, IgA and IgM concentrations against SARS-CoV-2 antigens in nasal mucosal lining fluid at the various sampling time points; - Local reactions at injection site or systemic reactions after COVID-19 vaccination; - T-cell responses and monocyte cytokine response to ex vivo stimulation at the various time points.
|
- Geometrische gemiddelde concentratie van receptor-bindend domein (RBD-) en S-specifieke IgG, IgA en IGM antilichamen in het serum op dag 21, 35, na 6 maanden en na 12 maanden; - IgG, IgA en IgM concentraties tegen SARS-CoV-2 antigenen in slijmvlies van de neus op verschillende tijdspunten; - Lokale of systemische reacties na COVID-19 vaccinatie. - T-cel reactie en monocyt cytokine reactie na ex vivo stimulatie op verschillende tijdspunten. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary analyses will need data from follow-up of the study and will be performed at the end of the study. |
Voor de analyse van de secundaire eindpunten is follow-up data nodig en zij zullen na afloop van de studie geanalyseerd worden. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Nooit BCG vaccinatie gehad |
Never received BCG vaccination |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study ends after the last blood collection. This is time point 4, one year after the first injection of the COVID-19 vaccine. |
De studie eindigt een jaar na de laatste bloedverzameling. Dat is tijdstip 4, een jaar na de eerste injectie van het COVID-19 vaccin. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |